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ABSTRACT: The transcription factor RUNX3 is a prominent regulator of multiple 
hematopoietic cell lineages. Gene loss of function studies demonstrated the unique and 
essential roles of this master regulator in differentiated lymphoid and myeloid cells. As a 
complementary approach, RUNX3 was upregulated in various leukocyte subsets to probe the 
instructive role of this ‘multi-lineage’ specific transcription factor. In this report, we overview 
the immunomodulatory functions of RUNX3 within the hematopoietic compartment to get 
insight to the consequences of Runx3 deletion or overexpression in committed immune cells. 
Genetic studies revealed the essential role of RUNX3 in Langerhans cell development, 
moreover, this transcription factor is necessary for the differentiation and maintenance of the 
cytotoxic CD8+ T cells, in addition, T helper, natural killer and B cells are also influenced by 
RUNX3. Importantly, the ectopic expression of Runx3 enhances the immunogenicity of 
cytotoxic T cells and pluripotent stem cell derived dendritic cells suggesting that this protein 
can be applied in cell based immunotherapies. 
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I. INTRODUCTION 
Runt-related transcription factors (RUNXs) represent an ancient protein family, which was 
detected in many metazoan animals.1 Three distinct mammalian RUNX proteins were 
identified, termed as RUNX1 (also known as AML1 or CBFα2), RUNX2 (AML3 or CBFα1) 
and RUNX3 (AML2 or CBFα3), each of them encoded by separate genes. RUNXs are 
orthologous to the Runt protein of Drosophila containing a conserved ‘runt domain’, which 
mediates DNA binding to a specific consensus sequence (TGt/cGGt/c) or its extended/altered 
versions of this core motif.1-3 RUNX binding elements are frequently located within gene 
regulatory regions (promoters and enhancers) and are implicated in transcriptional activation 
or repression. For example, RUNX proteins contribute to gene activation by recruiting histone 
acetyltransferase containing coactivator complexes such as p300, CBP, MOZ and MORF.4, 5 
On the other hand, RUNXs often elicit suppressive effects on gene expression via binding of 
the TLE or the mSIN3 corepressors.6-9 A specific peptide sequence (VWRPY) of the RUNX 
C-terminal part acts as a platform to recruit the TLE corepressor.9 Moreover, this transcription 
factor family contributes to gene silencing by recruiting the SUV39H1 histone 
methyltransferase which catalyzes the formation of the repressive H3K9 histone 
methylation.10, 11 Finally, histone deacetylase containing corepressor complexes also interact 
with the RUNX proteins and together they can elicit epigenetic silencing.12 
In addition to the coregulators, RUNX proteins interact with the core binding factor-β (CBF-
β), a non-DNA-binding RUNX partner, which increases the affinity and specificity of their 
DNA binding.13, 14 Moreover, RUNX proteins could collaborate with additional transcription 
factors to orchestrate gene expression on composite regulatory elements (e.g. ETS-RUNX or 
AP1-RUNX).15, 16 Thus, RUNX proteins have the potential to operate in numerous signaling 
events and lineage specific gene regulatory networks. Mammalian RUNX proteins have a 
distinct tissue-specific expression pattern, although overlapping expressions of the three 
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RUNXs have also been found.17 For example, RUNX1 can be detected in hematopoietic stem 
cells (HSCs) and hemogenic endothelial cells of arteries and aorta, in addition, RUNX1 is 
expressed in numerous blood cell lineages including myeloid, B- and T-lymphoid cells.17, 18 
RUNX2 is present in chondrocytes, osteoblasts and mesenchymal tissues, but this protein can 
also be detected in several blood cell lineages including T cells.19 RUNX3 is expressed in 
multiple hematopoietic lineages as well as in numerous tissues including cranial and dorsal 
root ganglia, thymus, chondrocytes, and the mesenchyme of epidermal appendages.17 Despite 
the overlapping expression pattern, RUNXs have their own well-defined functions in the 
course of lineage specification in mammals. RUNX1 is required for definitive hematopoiesis 
and represents the most frequent target of chromosomal translocations in leukemias.18, 20 
RUNX2 has been identified as a master regulator of bone differentiation, and its 
haploinsufficiency is able to cause abnormal bone formation (cleidocranial dysplasia).21, 22 
Runx3 null mice exhibit ataxia due to the loss of TrkC proprioceptive neurons in the dorsal 
root ganglia.23, 24 Of note, RUNX transcription factors also exhibit many additional functions. 
For example, RUNX3 is required for the proper development of cytotoxic T-lymphocytes and 
Langerhans cells as we will discuss in this paper. To define the specific role of RUNX3, loss 
of function studies were carried out by using Runx3-deficient mice (including tissue-specific 
knock out animals) or engineered cell lines. As a complementary genetic approach, Runx3 
was overexpressed in various cell lines as well as in transgenic animals. In this article we first 
overview the specific roles of RUNX3 in the hematopoietic compartment, followed by 
tackling the role of RUNX3 in committed immune cells. We also aimed to highlight the 
immunoregulatory potential of this ‘multi-lineage’ specific transcription factor in both 
lymphoid and myeloid cells. 
II. CONTRIBUTION OF RUNX3 TO STEADY STATE HEMATOPOIESIS 
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Before we start to discuss the specific functions of Runx3 in committed blood cell lineages, it 
is important to stress that this transcription factor also has a putative regulatory function 
during steady state hematopoiesis. HSCs have the potential to give rise to committed 
progenitors, which differentiate progressively to various blood cell types. Even though the 
origin of HSCs is still controversial, several transcription factors are able to regulate the 
development and the maintenance of this special stem cell type.25, 26 A large number of studies 
demonstrated that RUNX1 exerts a prominent role on HSC specification and on the onset of 
definitive hematopoiesis during embryogenesis.18, 27 However, RUNX3 plays only a marginal 
role at this stage, because it is barely expressed in the yolk-sack blood islands and in 
embryonic HSC precursor cells.28 In addition to this finding, embryonic lethality was 
observed in Runx1, but is absent in Runx3 null embryos due to impaired hematopoietic 
development.18 However, in contrast to early embryonic blood cells, Runx3 could readily be 
detected in fetal liver and also in adult HSCs and its expression pattern overlapped with 
Runx1.28 In agreement with these results, Wang et al. described that the concurrent 
elimination of Runx1 and Runx3 elicited a stronger hematopoietic phenotype in adult animals 
as compared to the Runx1 null mice. Runx1/Runx3 double knock out mice exhibited a lethal 
phenotypes due to bone marrow failure or to myeloproliferative disorder.29 Unexpectedly, the 
double KO cells showed mitomycin C hypersensitivity associated with some repair proteins 
defectively recruited to damaged DNA sites. This finding suggests that Runx1/Runx3 
composite gene deficiency leads to corrupted hematopoiesis due to the impaired DNA repair 
and genomic toxicity.29 An additional study also supported the role of RUNX3 in blood cell 
development: elevated number of hematopoietic progenitors as well as enhanced myeloid cell 
proliferation was detected in Runx3 (Mx1-Cre) single knockout mice leading to a 
myeloproliferative disorder in aged animals.30 Finally, reduced number of blood cells was 
observed in runx3-depleted Zebrafish embryos, whereas overexpression of runx3 led to the 
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enhanced formation of runx1 expressing blood cell precursors.31 In zebrafish, runx1 also acts 
as a key hematopoietic regulator, thus in this vertebrate model runx3 stimulates definitive 
hematopoiesis presumably indirectly via the activation of runx1.32 
In summary, the prevailing view suggests that RUNX1 is a master regulator of hematopoiesis, 
but in some cases RUNX3 may also participate in the modulation of steady state blood cell 
development presumably in cooperation with RUNX1. Considering that RUNX3 exhibits 
numerous unique functions in differentiated immune cells, in the following sections the 
regulatory roles of RUNX3 in committed myeloid and lymphoid cells will be described. 
III. RUNX3 MODULATED DENDRITIC CELL ACTIVATION AND LANGERHANS 
CELL DEVELOPMENT 
Runx3 is expressed in numerous myeloid cell types including dendritic cells (DCs), which can 
be classified as conventional and plasmacytoid DCs. In addition to this canonic function, DC 
like cells can also be generated ex vivo from monocytes (moDCs), bone marrow cells (BM-
DCs) or pluripotent embryonic stem cells (ES-DCs). Runx3 exerts an instructive role on the 
conventional CD4+ DC activation, while Runx3-deficient splenic DCs exhibit impaired major 
histocompatibility complex class II (MHCII) expression and T cell priming activity. 
Preferentially the Esam++ splenic DCs were underrepresented in Runx3-deleted animals 
suggesting that RUNX3 positively regulates the development and the immunogenicity of this 
particular DC subtype.33 Consistent with this view, we observed that ectopic expression of 
Runx3 was able to enhance the maturation potential of mouse ES cell-derived DCs (ES-DCs). 
RUNX3-instructed ES-DCs exhibited elevated expression levels of MHCII/CD80 and CD86, 
and these ex vivo differentiated cells displayed enhanced migratory capacity and superior T 
cell priming activity.34 Remarkably, in human moDCs RUNX3 overexpression led to the 
elevated expression of CD11a/CD18 and CD49d and might contribute to the elevated 
migratory, antigen presenting and T-cell stimulatory capacities of these cells.35 In contrast to 
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these positive effects, TGF-β instructed, Runx3-null BM-DCs displayed accelerated 
maturation and enhanced potency to stimulate T-cells suggesting that RUNX3 could interfere 
with the TGF-β dependent DC maturation.36 In line with this result, the chemokine receptor 
CCR7 was upregulated in Runx3-null DCs, which led to increased accumulation of activated 
DCs in the lung draining lymph nodes, and this contributed to the enhanced allergic airway 
inflammation.37 Collectively, these findings indicate that DC maturation can either be 
accelerated or inhibited depending on the DC subtypes as well as the environmental cues (Fig. 
1). Further kinetic and genomic analyses are needed to define the exact molecular functions 
acting RUNX3 in the course of DC activation. 
The TGF-β pathway has previously been shown to get modulated by RUNX3, and this 
signaling pathway is also critical for the maintenance of the Langerhans cell (LC) 
compartment.38-40 LCs belong to mononuclear phagocytic cells localized to the epidermis and 
are classified as macrophages originated from yolk sac-derived myeloid precursors and/or 
fetal monocytes.41 However, unlike classical macrophages but similar to DCs, LCs are 
capable to migrate to lymph nodes and present antigens to T cells. Interestingly, Fainaru and 
his colleagues observed that LCs were missing completely from the epidermis of Runx3-null 
mice.36 An additional study confirmed this finding and observed that the forced expression of 
Runx3 rescues the differentiation of bone marrow-derived LCs even in the absence of Pu.1.42 
These results strongly suggest that RUNX3 is a critical regulator of the LC development, even 
though most of the mechanistic data were extracted from bone marrow derived ex vivo 
differentiated LC-like cells. In future experiments it would be interesting to probe other 
effects of Runx3 by using bona fide LC precursors. 
IV. RUNX3-DRIVEN CYTOTOXIC T CELL DEVELOPMENT 
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In mammals CD8+ T lymphocytes represent the key cytotoxic cell phenotype of the adaptive 
immune system. These effector T cells are derived from bi-potential CD4/CD8 double 
positive precursors, which undergo positive selection through T cell receptor (TCR) 
interactions with the MHC proteins in the thymus. Thereafter, the post-selected precursor T 
cells become diverted to CD4+ (helper) or CD8+ (cytotoxic) single positive T-cells. Those T 
cells, which receive signals from MHCII-restricted TCRs differentiate to CD4+, whereas T 
cells activated by MHCI-restricted TCRs differentiate to CD8+ T cells. Regardless of the 
specificity of the TCR, the selection of T cell fate can be compromised in the absence of some 
lineage specific transcription factors. In this context genetic studies demonstrated the central 
role of RUNX3 in the lineage commitment of CD8+ effector T cells. While the Runx3-null 
animals exhibited reduced number of CD8+ cytotoxic T cells and the recovered CD8+ cells 
possessed impaired proliferative and cytotoxic potential.43, 44 RUNX3 dependent lineage 
selection is mediated partially by the suppression of CD4+ T cell fate together with RUNX3 
acting as a direct transcriptional repressor on the CD4 gene via the binding to a specific 
silencer element.44 Consistent with this finding, a subset of the Runx3-null CD8+ positive T 
cells exhibited retained CD4 expression.43 To examine the molecular mechanism of the 
RUNX3 dependent CD4 regulation, it was found that the suppression of this gene was 
depended on the VWRPY motif of the RUNX3 protein.45 The VWRPY penta-peptide can act 
as a docking module for the TLE corepressor complex, and this interaction is essential for the 
RUNX3-dependent CD4 silencing. In addition to CD4 suppression, Th-POK, the master 
regulator of CD4+ T cell development, is also repressed by RUNX3.46 Strikingly, Runx3 is 
suppressed by Th-POK indicating that these two key T-cell regulators antagonize with each 
other mutually.47, 48 These results suggest that post selected T cells, which express Runx3, 
repress the CD4+ T cell specific pathway and remain committed to the CD8+ cytotoxic T cell 
program. In agreement with this, RUNX3 is readily detected in CD8+ but not in CD4+ T 
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cells. However, it is still poorly defined which signaling pathways initiate the Runx3 
expression upon the commitment of the cytotoxic T cells. The prevailing view is consistent 
with the kinetic signaling model, which suggests that TCR signaling of CD4/CD8 double 
positive thymocytes terminates CD8 expression and thus allows CD8-dependent TCR 
signaling to cease. Termination of TCR signaling allows the releases of intra-thymic 
cytokines such as IL-7, while induces Runx3 expression, which specifies the CD8+ lineage 
fate.49 In addition to the aforementioned RUNX3 regulated genes (CD4 and Th-POK), many 
other putative RUNX3 target genes could also be operative in CD8+ T cells. A genome-scale 
gene expression analysis revealed that several hundred genes exhibited altered expression in 
both the Runx3-null resting and the cytokine activated T cells.16 Moreover, many follicular 
helper T cell (Tfh) affiliated genes (Tcf7, Bcl6, Maf, Il6ra, Cxcr5 and Il21) were turned on in 
Runx3-deficient CD8+ T cells suggesting that RUNX3 can mediate a general suppressive 
activity on the Tfh developmental program in committed cytotoxic T cells.50 This study 
revealed that Runx3 can establish a repressive trimethylated H3K27 chromatin mark in the 
regulatory regions of the Tfh specific genes. This Runx3 dependent epigenetic silencing 
contributes for the suppression of the Tfh program in cytotoxic T cells. In summary, loss of 
function genetic analyses demonstrated the critical role of RUNX3 during the selection of 
CD8+ T cell lineage integrity (Fig. 2). This set of data altogether marked that RUNX3 is able 
to exert broad suppressive effects on the T-helper and Tfh specific transcriptional programs in 
developing T cells. 
Interestingly, RUNX3 also activates the cytotoxic machinery in CD8+ T cells, and some of 
these positive effects were identified and characterized by gain of function studies. As an 
example, overexpression of RUNX3 positively regulated the CD103 expression in T cells.51 
In addition, the number of CD8+ T cells was elevated in Runx3 transgenic thymus 
demonstrating, that ectopic expression of this protein forced thymocytes to select the CD8+ 
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developmental pathway.52 Moreover, RUNX3 can directly stimulate this gene via the 
regulation of the stage specific enhancers of CD8.53 To carry on this study Sato and his 
colleagues have engineered a Runx3 transgenic, as well as a dominant negative Runt domain 
expressing mouse strain. As expected, the presence of a dominant negative RUNX resulted in 
less CD8+ T cells from the CD4+CD8low post-selected cells, while the expression of the 
CD8 marker remained high in the committed T cells. Activation of naive CD8+ T cells, 
together with various peripheral antigens promoted the differentiation of these cells into 
cytolytic effector killer T cells. To characterize this process further, Runx3 was re-expressed 
retrovirally in CD8+ T cells derived from Runx3-null mice, and as expected, RUNX3 restore 
the expression of several cytotoxic T cell specific genes (Eomes, perforin, granzyme B, and 
IFNg).54 Moreover, this study revealed that Runx3 can bind to the putative regulatory 
elements of genes encoding perforin, granzyme B, and IFN-γ suggesting that these T cell 
specific genes are regulated by RUNX3 in effector T cells directly. Finally, overexpression of 
Runx3 was found to accelerate CD69+ CD103+ tissue resident memory T cell differentiation 
in vivo indicating that CD8+ memory T cell development is also modulated by this 
transcription factor.55 In conclusion, several gain of function studies confirmed that the 
RUNX3 mediated transcriptional program is necessary for the maintenance of effector and 
memory functions of cytotoxic T cells (Fig. 2). 
V. RUNX3 DEPENDENT TH1 POLARIZATION AND ENHANCED SUPPRESSIVE T 
CELL DEVELOPMENT 
Despite the general suppressive role of RUNX3 on CD4+ T cell development, curiously, this 
transcription factor is also involved in T helper cell polarization. Upon encountering and 
capturing antigen, naive CD4+ T helper (Th) cells become polarized to effector cell subsets, 
which exhibit distinct cytokine profiles. Non-polarized CD4+ T cells have the potential to 
differentiate into Th1, Th2, Th9, Th17 or follicular helper T cells in the periphery. 
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Furthermore, CD4+ T lymphocytes can give rise to immunosuppressive regulatory T (Treg) 
cells. The Th1 cells release IFN-γ and activate macrophages as well as CD8+ T cells to 
induce immunity against intracellular pathogens. Whereas, Th2 cells secrete IL-4, IL-5, IL-13 
and stimulate humoral responses against extracellular pathogens concomitant with isotype 
switching to immunoglobulin E (IgE).56 An early study demonstrated that ectopic expression 
of Runx1 negatively regulates Th2 polarization of splenic CD4+ T cells by suppressing Gata3 
expression while maintaining Th1 idendity.57 In contrast to these data, later it was suggested 
that Runx3 represents the principal RUNX component in Th1 cells, because this gene was 
upregulated during Th1 polarization, while Runx1 remained barely expressed in Th1 primed 
cells.58 Consistent with this, impaired IFN-γ production was detected in Runx3-null Th1 cells, 
whereas ectopically expressed Runx3 markedly potentiated T-bet dependent IFN-γ 
production. Curiously, RUNX3 also interfered with the Th2 expression of IL-4 via binding to 
the IL4 silencer (DNase I hypersensitivity site IV in the mouse IL4 locus).58 Furthermore, in 
the absence of Runx3 IL-4 was reactivated in non-polarized or Th1 skewed T helper cells, 
which provoked asthma-like symptoms due to accelerated Th2 responses.59 Several additional 
studies confirmed the instructive role of RUNX3 during Th1 polarization. For example, 
overexpression of Runx3 in CD4+ T-cells led to polarization to the Th1 phenotype even under 
conditions that promote Th2 differentiation via suppression of GATA3 transcriptional 
activity.60, 61 Opposing to these findings, the forced expression of Gata3 redirect CD4+ T cell 
development into IL-4 producing Th2 type cells via repressing the capacity of RUNX3 to 
induce Ifng expression. Finally, the transcription factor TWIST1 has the potential to regulate 
Th1 polarization negatively via interfering with RUNX3, while the forced expression of 
RUNX3 could revert the suppressive effect of TWIST1 exerted on IFN-γ production.62 In 
conclusion, RUNX3 acts as a positive regulator of murine Th1 polarization via the 
transcriptional stimulation of Ifng expression and the suppression of IL-4 production (Fig. 3). 
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Interestingly, RUNX3 resides in the human chromosome 1p36.1, a genomic region containing 
putative susceptibility genes for asthma, hence RUNX3 dysfunction might provoke 
accelerated Th2 responses in these patients.63 
In addition to Th1/Th2 polarization, RUNX3 also exhibits diverse roles on Th17 
development. Committed Th17 cells produce IL-17 and IL-22 cytokines to protect mucosal 
surfaces against extracellular pathogens; moreover, these cells are implicated in the 
development of various autoimmune diseases.64 Forced expression of Runx1 or Runx3 in 
differentiated Th17 cells were found to enhance the development of IL-17A and IFN-γ 
producing Th17 cells, conversely, Runx1 or Runx3 deficiency impaired the formation of IFN-
γ producing cells.65 These findings imply that both RUNX1 and RUNX3 have the potential to 
reprogram Th17 cells into pathogenic IL17/IFN-γ releasing cells, which are implicated in 
various autoimmune diseases. Contrary to these results, upregulation of Runx3 suppress Th17 
polarization, whereas Runx3-deleted CD4+ T cells conferred enhanced Th17 differentiation 
capacity suggesting that Runx3-instructed CD4+ T cells are highly tolerogenic and thus are 
able to deal with gut specific antigens without provoking inflammation.66 In agreement with 
the putative tolerogenic effects of this factor, several lines of evidence suggest that RUNX 
proteins facilitate the conversion of CD4+ T cells into immunosuppressive Treg cells. The 
RUNX1-Cbfβ heterodimer is a putative regulator of Treg cell functions because Cbfb-deleted 
Treg cells exhibit impaired T cell suppressive capacity; in addition, RUNX1 silenced human 
Treg cells expressed less FOXP3.67, 68 Despite of these findings, later studies also suggested 
the central role of RUNX3 in Treg cell generation. For example, ectopically expressed Runx3 
more consistently regulated the Foxp3 expression in Treg cells compared with Runx1.69 In 
addition, RUNX3 and FOXP3 were highly expressed in circulating human CD4+ CD25++ 
Treg cells.70 
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The possibility that RUNX3 promotes the differentiation of additional suppressive cell types, 
i.e. the intraepithelial lymphocytes (IELs) was also emerged. Retinoic acid and TGF-β could 
elicit the differentiation of CD8αα IEL cells in CD4+ T cells in a RUNX3-dependent 
manner.71 Furthermore, T-bet and RUNX3 together repressed CD4+ T helper cell functions 
and elicited the IEL program including the expression of CD8αα.72 These observations 
altogether suggest that the intestinal environment provides cues for RUNX3 dependent Treg 
and/or IEL cell differentiation. 
VI. RUNX3 INSTRUCTED NK CELL PROLIFERATION AND MATURATION 
Natural killer (NK) cells provide cytotoxic innate cell defense against virus-infected as well as 
transformed cells. Similarly to CD8+ cytotoxic T cells, RUNX3 is highly expressed in mouse 
and human NK cells and is able to modulate the activity of this blood cell lineage.73-75 It was 
documented that overexpression of a dominant negative RUNX protein reduced NK cell 
numbers in ex vivo differentiated cells. Furthermore, semimature (CD43highMac-1high) splenic 
NK cells were obtained from the dominant negative Runx gene carrying transgenic mice.73 A 
loss of function study confirmed the regulatory role of Runx3 on NK cell activation. Lower 
percentage of mature NK cells was detected in Runx3-null spleen, moreover, defective IL-15-
dependent NK cell proliferation and expansion was observed in the Runx3-deficient animals, 
preferentially in the uterus.75 Despite of these alterations, the remaining Runx3-deficient NK 
cells still exhibited normal cytotoxic activity. In agreement with these findings, forced 
expression of Runx3 was sufficient to preserve NK cell responses upon induction of brain 
ischemia suggesting that the sustained expression of Runx3 contributed to the maintenance of 
NK cell function in vivo.76 
RUNX3 can directly modulates the transcription of Ncr1 (also known as NKp46) an NK cell 
affiliated gene via binding to promoter specific RUNX response elements.77 This study also 
described that a dominant negative form of RUNX was able to repress Ncr1 expression, 
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whereas, overexpression of RUNX3 positively regulated the NKp46 level in a murine NK cell 
line (KY-2). To further characterize the genomic impact of RUNX3 on NK cells a genome-
wide gene expression analysis was employed. This study revealed that 891 genes exhibited 
altered expression in Runx3-deleted splenic NK cells.75 More importantly, 73% of the altered 
genes could regulate this factor directly, since RUNX3 occupancy was detected in the 
regulatory regions of these genes. However, further studies are needed to characterize the 
contribution of these putative RUNX3 regulated genes on NK cell development and activity. 
Moreover, it will be important to probe those common targets, which are modulated by 
RUNX3 similarly to cytotoxic CD8+ T cells as compared to NK cells.16 In summary, NK cell 
maturation and proliferation can be modified with RUNX3 (Fig. 4), however the genomic 
targets of these factors is still poorly characterized in NK cells. 
Finally it is worth mentioning that RUNX3 regulates the development of two additional innate 
lymphoid cell types. Deletion of Runx3 from NKp46-expressing cells, results in innate 
lymphoid cell type 1 (ILC1) and cell type 3 (ILC3) deficiency. It seems that RUNX3 can 
maintain the survival of ILC1 cells, and this factor also governs the differentiation of ILC3 
via regulation of RORγ expression.78 
VII. RUNX3 DEPENDENT B CELL PROLIFERATION AND IMMUNGLOBULIN-A 
CLASS SWITCH 
Accumulating evidence indicates that the Epstein-Barr virus (EBV) provoked B cell 
proliferation is influenced by RUNX3. In the course of EBV infection, the viral transcription 
factor EBNA2 activates RUNX3 expression through a specific DNA element within a super-
enhancer.79, 80 In addition to this observation, virus induced RUNX3 can downregulate the 
expression of RUNX1 via the P1 promoter specific response element in B lymphoid cells.81 
Of note, the impaired RUNX1 expression is correlated with the enhanced B cell proliferation. 
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The authors of these reports suggested that RUNX3 positively regulates the EBV-mediated B 
cell expansion and immortalization (Fig. 4) probably via the repression of RUNX1 
expression. 
In addition to cell proliferation, RUNX3 can also regulate the immunoglobulin A (IgA) class 
switch recombination in B cells. IgA antibodies are preferentially produced by gut associated 
B cells, protect against mucosal pathogens and modulate the size and composition of the 
intestinal microbiome. B cells can undergo IgA class switch recombination upon CD40-
CD40L ligation promoted by TGF-β signaling.82 Remarkably, RUNX3 is part of the TGF-β 
dependent complex, and binds to the promoter of the mouse germline Ig α gene thus 
stimulating the transcription of Ig α in splenic B and I.29µ cells.83 It is worth mentioning that 
the transcription of germline Ig α is a pre-requisite for the IgA class switch recombination.84 
Additional studies also confirmed that TGF-β activated SMAD2, 3 and RUNX3 can 
cooperate at the promoter of the germline Ig α gene and together they stimulate Ig α 
transcription.85-87 In accord with these results, impaired IgA class switch recombination was 
detected in Runx3-deleted splenic B cells in vitro.36 Unexpectedly, Runx3-null mice were 
found to produced more IgA in vivo suggesting that other RUNX proteins might compensate 
for Runx3-deficiency upon IgA class switch recombination36. In agreement with this, impaired 
IgA production was detected in Runx2/Runx3 double-deficient animals, and the retinoic acid- 
or the TGF-β-dependent inductions of germline Ig α transcription were also blocked in the 
absence of Runx2/Runx3. Moreover, re-expression of either Runx2 or Runx3 retained the IgA 
producing capacity of these B cells suggesting that both RUNX2 and RUNX3 modulate the 
TGF-β-dependent IgA class switch recombination in murine B cells.88 
VIII. RUNX-DRIVEN LINEAGE CONVERSIONS AND IMMUNE CELL 
MATURATION 
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In this report we presented several examples for functional alterations in immune cells due to 
the overexpression or deletion of RUNX3. These cell type specific genetic modifications 
helped us to define the steady state and the pathological roles of this important regulatory 
protein. Of note, nowadays overexpression of transcription factors has become a feasible and 
robust tool to manipulate cell fate choices especially after the discovery that exogenously 
added factors could reprogram differentiated cells into induced pluripotent stem (iPS) cells.89 
This seminal discovery has altered fundamental ideas on the stability of cellular identity, 
stimulating novel cell reprogramming strategies including direct lineage conversions.90, 91 In 
this context, fibroblasts could successfully be transdifferentiated to cardiomyocytes or 
neurons with a cocktail of cardiac or neuronal specific transcription factors, respectively.92, 93 
Moreover, fibroblasts were reconverted to hematopoietic cells with transcription factor 
mediated lineage reporgramming.94-97 In addition, pluripotent stem cell-derived blood cell 
differentiation was improved with ectopically expressed transcription factors.34, 98-103  
To modify cellular identity, the core gene regulatory networks need proper reactivation with 
lineage determining (pioneer) transcription factors.104 In case of neuronal reprogramming 
Ascl1 acts as a lineage determining transcription factor, while engineering fibroblast derived 
liver cells Foxa1-3 were considered as pioneer transcription factors.105, 106 Importantly, 
lineage determining transcription factors by themselves are usually not sufficient to generate 
functional target cells, additional maturation promoting transcription factors are required to 
stimulate the formation of fully mature cells.90 Interestingly, RUNX1 is an active component 
of several transcription factor cocktails, which have previously been used to engineer 
hematopoietic cells derived from fibroblasts, endothelial cells or pluripotent stem cells.94, 101, 
107, 108 Until now, the hierarchy of the selected transcription factors has not been determined in 
these blood cell conversion studies. However, it is well known that RUNX1 plays a pivotal 
role in transforming the hemogenic endothelium to hematopoietic cells, suggesting that 
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RUNX1 acts as a blood lineage determining transcription factor.18 In contrast to RUNX1, our 
analysis suggested that RUNX3 can be classified as a maturation promoting factor in the 
course of ES-DC development. During the ex vivo differentiation process, PU.1 and Irf8 were 
identified as highly expressed genes in ES-DCs, and these two pioneer transcription factors 
might be able to drive the development of these cells.34 Even though ex vivo differentiated 
DCs had a limited T cell activating potential, the enforced expression of RUNX3 still could 
facilitate strong DC dependent immunogenicity suggesting that RUNX3 acts as a bona fide 
maturation factor in this pluripotent stem cell derived DC differentiation model. Of note, 
RUNX3 also stimulates the differentiation and the cytotoxic activity of CD8+ T and NK cells. 
Thus it seems feasible, that the forced expression of RUNX3 could facilitate the maturation of 
the cytolytic effector cells. Importantly, fully mature immune cells could be harnessed for 
cell-based immunotherapies. 
Immunotherapy represents a powerful weapon against many cancer types. For example, ex 
vivo generated autologous DCs, were pulsed with tumor antigens and injected back into 
cancer patients to boost antitumor adaptive immune response. Some of these DC-based 
vaccines have been shown promising clinical outcomes.109 In addition, immune checkpoint 
inhibitor antibodies were applied to facilitate T-cell response by antagonizing co-inhibitory 
signals (for example, CTLA-4 or PD1/PD-L1). Strikingly, durable responses were observed in 
increasing numbers of tumors upon the application of these checkpoint blockers.110, 111 
Finally, adoptive cell therapies were employed using tumor infiltrating lymphocytes or the 
patient’s peripheral T cells were engineered to target cancer specific antigens, via 
physiological T cell receptors or chimeric antigen receptors (CARs).112 Importantly, recent 
clinical trials with CD19 targeting CAR T cells has shown a remarkable, 90% remission in 
patients with acute B lymphoblastic leukemia, underscoring the great potential of this cell-
based therapeutic strategy.113 However, despite the high rate of response observed with these 
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novel methods, unfortunately, a few patients failed to response to these treatments and many 
responders relapsed after a longer period of time suggesting that these protocols must be 
further optimized.114 Genetically encoded tools like ectopically expressed transcription factors 
may allow cell engineers to boost the survival and the immunogenicity of the ex vivo 
manufactured immune cells. 
RUNX3 has a critical regulatory role in cytotoxic T cells, raising the possibility that this 
particular transcription factor could be harnessed for cellular therapy. In agreement with this, 
overexpression of RUNX3 in adoptively transferred murine T cells enhanced the abundance 
of tumor infiltrating lymphocytes and impacted tumor growth negatively suggesting, that 
RUNX3 activation or overexpression can be used to ameliorate the anticancer response.55 In 
addition, our results indicated that RUNX3-instructed ES-DCs exhibited a superior T cell 
activation capacity which may be beneficial to provoke antitumor response.34 In the future, 
these murine data must be extended with human studies to prove or disprove the therapeutic 
potential of the RUNX3-primed antigen presenting or cytotoxic T cells. 
IX. CONCLUSIONS 
In this review we have analyzed the immunoregulatory functions of RUNX3 in various 
lymphocyte and dendritic cell subsets. Genetic perturbation of Runx3 helped us to understand 
the diverse roles of this transcriptional regulator in both lymphoid and myeloid cells. In many 
cases RUNX3 exhibits overlapping functions with RUNX1 but RUNX3 also exerts several 
unique and essential roles in committed immune cells. To understand the diverse molecular 
functions of this important factor, numerous RUNX3 target genes and pathways have already 
been identified in various immune cell types and transgenic models but the RUNX3 
dependent genome-wide transcriptional and epigenetic program is just beginning to be 
elucidated. Additional ChIP-seq analyses of RUNX3 binding and histone modifications would 
be needed for the identification and characterization of novel immune cell-specific RUNX 
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genomic regulatory elements. Moreover, these gene expression analyses must be expanded 
with single cell genomic approaches to further elucidate the cell type specific roles of this 
master gene. In addition, increased number of human data would be needed to uncover the 
possible pathological roles of RUNX3 in immune cell disorders. Finally, RUNX3 can 
facilitate the terminal differentiation and/or the maturation of cytotoxic T lymphocytes and 
some DC subsets. Based on this, the forced expression or the reactivation of RUNX3 might be 
applied for developing immunotherapeutic approaches to provoke relevant immune cell 
responses able to be used in clinical settings. 
ACKNOWLEDGEMENTS 
The authors are grateful to Drs. Éva Rajnavölgyi and Lajos Széles (University of Debrecen) 
for suggestions and comments on the manuscript. This work was supported by Hungarian 
Scientific Research Funds (NKFIH K124890 and GINOP-2.3.2-15-2016-00044 
PHARMPROT). 
CONFLICT OF INTEREST 
The authors declare that they have no conflict of interest. 
REFERENCES 
 
 
1. Hughes S, Woollard A. RUNX in Invertebrates. Adv Exp Med Biol. 2017;962:3-18. PubMed 
PMID: 28299647. 
2. Tahirov TH, Inoue-Bungo T, Morii H, Fujikawa A, Sasaki M, Kimura K, Shiina M, Sato K, 
Kumasaka T, Yamamoto M, Ishii S, Ogata K. Structural analyses of DNA recognition by the 
AML1/Runx-1 Runt domain and its allosteric control by CBFbeta. Cell. 2001 Mar 09;104(5):755-67. 
PubMed PMID: 11257229. 
3. Bowers SR, Calero-Nieto FJ, Valeaux S, Fernandez-Fuentes N, Cockerill PN. Runx1 binds as a 
dimeric complex to overlapping Runx1 sites within a palindromic element in the human GM-CSF 
enhancer. Nucleic Acids Res. 2010 Oct;38(18):6124-34. PubMed PMID: 20483917. PMCID: 
PMC2952845. 
4. Yang XJ. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and 
other diseases. Nucleic Acids Res. 2004;32(3):959-76. PubMed PMID: 14960713. PMCID: PMC384351. 
20 
 
5. Kitabayashi I, Yokoyama A, Shimizu K, Ohki M. Interaction and functional cooperation of the 
leukemia-associated factors AML1 and p300 in myeloid cell differentiation. The EMBO journal. 1998 
Jun 1;17(11):2994-3004. PubMed PMID: 9606182. PMCID: PMC1170639. 
6. Yarmus M, Woolf E, Bernstein Y, Fainaru O, Negreanu V, Levanon D, Groner Y. 
Groucho/transducin-like Enhancer-of-split (TLE)-dependent and -independent transcriptional 
regulation by Runx3. Proc Natl Acad Sci U S A. 2006 May 09;103(19):7384-9. PubMed PMID: 
16651517. PMCID: PMC1464349. 
7. Imai Y, Kurokawa M, Yamaguchi Y, Izutsu K, Nitta E, Mitani K, Satake M, Noda T, Ito Y, Hirai H. 
The corepressor mSin3A regulates phosphorylation-induced activation, intranuclear location, and 
stability of AML1. Mol Cell Biol. 2004 Feb;24(3):1033-43. PubMed PMID: 14729951. PMCID: 
PMC321417. 
8. Lutterbach B, Westendorf JJ, Linggi B, Isaac S, Seto E, Hiebert SW. A mechanism of repression 
by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J 
Biol Chem. 2000 Jan 7;275(1):651-6. PubMed PMID: 10617663. 
9. Javed A, Guo B, Hiebert S, Choi JY, Green J, Zhao SC, Osborne MA, Stifani S, Stein JL, Lian JB, 
van Wijnen AJ, Stein GS. Groucho/TLE/R-esp proteins associate with the nuclear matrix and repress 
RUNX (CBF(alpha)/AML/PEBP2(alpha)) dependent activation of tissue-specific gene transcription. J 
Cell Sci. 2000 Jun;113 ( Pt 12):2221-31. PubMed PMID: 10825294. 
10. Reed-Inderbitzin E, Moreno-Miralles I, Vanden-Eynden SK, Xie J, Lutterbach B, Durst-Goodwin 
KL, Luce KS, Irvin BJ, Cleary ML, Brandt SJ, Hiebert SW. RUNX1 associates with histone deacetylases 
and SUV39H1 to repress transcription. Oncogene. 2006 Sep 21;25(42):5777-86. PubMed PMID: 
16652147. 
11. Chakraborty S, Sinha KK, Senyuk V, Nucifora G. SUV39H1 interacts with AML1 and abrogates 
AML1 transactivity. AML1 is methylated in vivo. Oncogene. 2003 Aug 14;22(34):5229-37. PubMed 
PMID: 12917624. 
12. Durst KL, Hiebert SW. Role of RUNX family members in transcriptional repression and gene 
silencing. Oncogene. 2004 May 24;23(24):4220-4. PubMed PMID: 15156176. 
13. Kagoshima H, Nimmo R, Saad N, Tanaka J, Miwa Y, Mitani S, Kohara Y, Woollard A. The C. 
elegans CBFbeta homologue BRO-1 interacts with the Runx factor, RNT-1, to promote stem cell 
proliferation and self-renewal. Development. 2007 Nov;134(21):3905-15. PubMed PMID: 17933794. 
14. Golling G, Li L, Pepling M, Stebbins M, Gergen JP. Drosophila homologs of the proto-
oncogene product PEBP2/CBF beta regulate the DNA-binding properties of Runt. Mol Cell Biol. 1996 
Mar;16(3):932-42. PubMed PMID: 8622696. PMCID: PMC231075. 
15. Wotton D, Ghysdael J, Wang S, Speck NA, Owen MJ. Cooperative binding of Ets-1 and core 
binding factor to DNA. Mol Cell Biol. 1994 Jan;14(1):840-50. PubMed PMID: 8264651. PMCID: 
PMC358432. 
16. Lotem J, Levanon D, Negreanu V, Leshkowitz D, Friedlander G, Groner Y. Runx3-mediated 
transcriptional program in cytotoxic lymphocytes. PLoS One. 2013;8(11):e80467. PubMed PMID: 
24236182. PMCID: PMC3827420. 
17. Levanon D, Groner Y. Structure and regulated expression of mammalian RUNX genes. 
Oncogene. 2004 May 24;23(24):4211-9. PubMed PMID: 15156175. 
18. de Bruijn M, Dzierzak E. Runx transcription factors in the development and function of the 
definitive hematopoietic system. Blood. 2017 Apr 13;129(15):2061-9. PubMed PMID: 28179276. 
19. Vaillant F, Blyth K, Andrew L, Neil JC, Cameron ER. Enforced expression of Runx2 perturbs T 
cell development at a stage coincident with beta-selection. J Immunol. 2002 Sep 15;169(6):2866-74. 
PubMed PMID: 12218099. 
20. Sood R, Kamikubo Y, Liu P. Role of RUNX1 in hematological malignancies. Blood. 2017 Apr 
13;129(15):2070-82. PubMed PMID: 28179279. PMCID: PMC5391618. 
21. Komori T. Regulation of osteoblast differentiation by transcription factors. J Cell Biochem. 
2006 Dec 01;99(5):1233-9. PubMed PMID: 16795049. 
22. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington 
RS, Mundlos S, Olsen BR, Selby PB, Owen MJ. Cbfa1, a candidate gene for cleidocranial dysplasia 
21 
 
syndrome, is essential for osteoblast differentiation and bone development. Cell. 1997 May 
30;89(5):765-71. PubMed PMID: 9182764. 
23. Levanon D, Bettoun D, Harris-Cerruti C, Woolf E, Negreanu V, Eilam R, Bernstein Y, 
Goldenberg D, Xiao C, Fliegauf M, Kremer E, Otto F, Brenner O, Lev-Tov A, Groner Y. The Runx3 
transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. The 
EMBO journal. 2002 Jul 01;21(13):3454-63. PubMed PMID: 12093746. PMCID: PMC125397. 
24. Inoue K, Ozaki S, Shiga T, Ito K, Masuda T, Okado N, Iseda T, Kawaguchi S, Ogawa M, Bae SC, 
Yamashita N, Itohara S, Kudo N, Ito Y. Runx3 controls the axonal projection of proprioceptive dorsal 
root ganglion neurons. Nat Neurosci. 2002 Oct;5(10):946-54. PubMed PMID: 12352981. 
25. Gottgens B. Regulatory network control of blood stem cells. Blood. 2015 Apr 
23;125(17):2614-20. PubMed PMID: 25762179. 
26. Dzierzak E, Speck NA. Of lineage and legacy: the development of mammalian hematopoietic 
stem cells. Nat Immunol. 2008 Feb;9(2):129-36. PubMed PMID: 18204427. PMCID: PMC2696344. 
27. Tober J, Maijenburg MW, Speck NA. Taking the Leap: Runx1 in the Formation of Blood from 
Endothelium. Curr Top Dev Biol. 2016;118:113-62. PubMed PMID: 27137656. 
28. Landry JR, Kinston S, Knezevic K, de Bruijn MF, Wilson N, Nottingham WT, Peitz M, Edenhofer 
F, Pimanda JE, Ottersbach K, Gottgens B. Runx genes are direct targets of Scl/Tal1 in the yolk sac and 
fetal liver. Blood. 2008 Mar 15;111(6):3005-14. PubMed PMID: 18184866. 
29. Wang CQ, Krishnan V, Tay LS, Chin DW, Koh CP, Chooi JY, Nah GS, Du L, Jacob B, Yamashita N, 
Lai SK, Tan TZ, Mori S, Tanuichi I, Tergaonkar V, Ito Y, Osato M. Disruption of Runx1 and Runx3 leads 
to bone marrow failure and leukemia predisposition due to transcriptional and DNA repair defects. 
Cell Rep. 2014 Aug 07;8(3):767-82. PubMed PMID: 25066130. 
30. Wang CQ, Motoda L, Satake M, Ito Y, Taniuchi I, Tergaonkar V, Osato M. Runx3 deficiency 
results in myeloproliferative disorder in aged mice. Blood. 2013 Jul 25;122(4):562-6. PubMed PMID: 
23741011. 
31. Kalev-Zylinska ML, Horsfield JA, Flores MV, Postlethwait JH, Chau JY, Cattin PM, Vitas MR, 
Crosier PS, Crosier KE. Runx3 is required for hematopoietic development in zebrafish. Dev Dyn. 2003 
Nov;228(3):323-36. PubMed PMID: 14579373. 
32. Kissa K, Herbomel P. Blood stem cells emerge from aortic endothelium by a novel type of cell 
transition. Nature. 2010 Mar 04;464(7285):112-5. PubMed PMID: 20154732. 
33. Dicken J, Mildner A, Leshkowitz D, Touw IP, Hantisteanu S, Jung S, Groner Y. Transcriptional 
reprogramming of CD11b+Esam(hi) dendritic cell identity and function by loss of Runx3. PLoS One. 
2013;8(10):e77490. PubMed PMID: 24204843. PMCID: 3817345. 
34. Takacs E, Boto P, Simo E, Csuth TI, Toth BM, Raveh-Amit H, Pap A, Kovacs EG, Kobolak J, 
Benko S, Dinnyes A, Szatmari I. Immunogenic Dendritic Cell Generation from Pluripotent Stem Cells 
by Ectopic Expression of Runx3. J Immunol. 2017 Jan 01;198(1):239-48. PubMed PMID: 27852743. 
35. Dominguez-Soto A, Relloso M, Vega MA, Corbi AL, Puig-Kroger A. RUNX3 regulates the 
activity of the CD11a and CD49d integrin gene promoters. Immunobiology. 2005;210(2-4):133-9. 
PubMed PMID: 16164020. 
36. Fainaru O, Woolf E, Lotem J, Yarmus M, Brenner O, Goldenberg D, Negreanu V, Bernstein Y, 
Levanon D, Jung S, Groner Y. Runx3 regulates mouse TGF-beta-mediated dendritic cell function and 
its absence results in airway inflammation. The EMBO journal. 2004 Feb 25;23(4):969-79. PubMed 
PMID: 14765120. PMCID: 380997. 
37. Fainaru O, Shseyov D, Hantisteanu S, Groner Y. Accelerated chemokine receptor 7-mediated 
dendritic cell migration in Runx3 knockout mice and the spontaneous development of asthma-like 
disease. Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10598-603. PubMed PMID: 16027362. PMCID: 
PMC1180803. 
38. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim 
HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, 
Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y. Causal relationship between the 
loss of RUNX3 expression and gastric cancer. Cell. 2002 Apr 05;109(1):113-24. PubMed PMID: 
11955451. 
22 
 
39. Borkowski TA, Letterio JJ, Farr AG, Udey MC. A role for endogenous transforming growth 
factor beta 1 in Langerhans cell biology: the skin of transforming growth factor beta 1 null mice is 
devoid of epidermal Langerhans cells. J Exp Med. 1996 Dec 1;184(6):2417-22. PubMed PMID: 
8976197. PMCID: PMC2196398. 
40. Sere K, Felker P, Hieronymus T, Zenke M. TGFbeta1 microenvironment determines dendritic 
cell development. Oncoimmunology. 2013 Mar 1;2(3):e23083. PubMed PMID: 23687620. PMCID: 
PMC3655738. 
41. Doebel T, Voisin B, Nagao K. Langerhans Cells - The Macrophage in Dendritic Cell Clothing. 
Trends Immunol. 2017 Nov;38(11):817-28. PubMed PMID: 28720426. 
42. Chopin M, Seillet C, Chevrier S, Wu L, Wang H, Morse HC, 3rd, Belz GT, Nutt SL. Langerhans 
cells are generated by two distinct PU.1-dependent transcriptional networks. The Journal of 
experimental medicine. 2013 Dec 16;210(13):2967-80. PubMed PMID: 24249112. PMCID: 3865480. 
43. Woolf E, Xiao C, Fainaru O, Lotem J, Rosen D, Negreanu V, Bernstein Y, Goldenberg D, 
Brenner O, Berke G, Levanon D, Groner Y. Runx3 and Runx1 are required for CD8 T cell development 
during thymopoiesis. Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7731-6. PubMed PMID: 
12796513. PMCID: PMC164656. 
44. Taniuchi I, Osato M, Egawa T, Sunshine MJ, Bae SC, Komori T, Ito Y, Littman DR. Differential 
requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte 
development. Cell. 2002 Nov 27;111(5):621-33. PubMed PMID: 12464175. 
45. Seo W, Tanaka H, Miyamoto C, Levanon D, Groner Y, Taniuchi I. Roles of VWRPY motif-
mediated gene repression by Runx proteins during T-cell development. Immunol Cell Biol. 2012 
Sep;90(8):827-30. PubMed PMID: 22370763. 
46. Setoguchi R, Tachibana M, Naoe Y, Muroi S, Akiyama K, Tezuka C, Okuda T, Taniuchi I. 
Repression of the transcription factor Th-POK by Runx complexes in cytotoxic T cell development. 
Science. 2008 Feb 08;319(5864):822-5. PubMed PMID: 18258917. 
47. Egawa T, Littman DR. ThPOK acts late in specification of the helper T cell lineage and 
suppresses Runx-mediated commitment to the cytotoxic T cell lineage. Nat Immunol. 2008 
Oct;9(10):1131-9. PubMed PMID: 18776905. PMCID: PMC2666788. 
48. Luckey MA, Kimura MY, Waickman AT, Feigenbaum L, Singer A, Park JH. The transcription 
factor ThPOK suppresses Runx3 and imposes CD4(+) lineage fate by inducing the SOCS suppressors of 
cytokine signaling. Nat Immunol. 2014 Jul;15(7):638-45. PubMed PMID: 24880459. 
49. Kimura MY, Thomas J, Tai X, Guinter TI, Shinzawa M, Etzensperger R, Li Z, Love P, Nakayama 
T, Singer A. Timing and duration of MHC I positive selection signals are adjusted in the thymus to 
prevent lineage errors. Nat Immunol. 2016 Dec;17(12):1415-23. PubMed PMID: 27668801. 
50. Shan Q, Zeng Z, Xing S, Li F, Hartwig SM, Gullicksrud JA, Kurup SP, Van Braeckel-Budimir N, Su 
Y, Martin MD, Varga SM, Taniuchi I, Harty JT, Peng W, Badovinac VP, Xue HH. The transcription factor 
Runx3 guards cytotoxic CD8+ effector T cells against deviation towards follicular helper T cell lineage. 
Nat Immunol. 2017 Jun 12. PubMed PMID: 28604718. 
51. Grueter B, Petter M, Egawa T, Laule-Kilian K, Aldrian CJ, Wuerch A, Ludwig Y, Fukuyama H, 
Wardemann H, Waldschuetz R, Moroy T, Taniuchi I, Steimle V, Littman DR, Ehlers M. Runx3 regulates 
integrin alpha E/CD103 and CD4 expression during development of CD4-/CD8+ T cells. J Immunol. 
2005 Aug 01;175(3):1694-705. PubMed PMID: 16034110. 
52. Kohu K, Sato T, Ohno S, Hayashi K, Uchino R, Abe N, Nakazato M, Yoshida N, Kikuchi T, 
Iwakura Y, Inoue Y, Watanabe T, Habu S, Satake M. Overexpression of the Runx3 transcription factor 
increases the proportion of mature thymocytes of the CD8 single-positive lineage. J Immunol. 2005 
Mar 01;174(5):2627-36. PubMed PMID: 15728469. 
53. Sato T, Ohno S, Hayashi T, Sato C, Kohu K, Satake M, Habu S. Dual functions of Runx proteins 
for reactivating CD8 and silencing CD4 at the commitment process into CD8 thymocytes. Immunity. 
2005 Mar;22(3):317-28. PubMed PMID: 15780989. 
54. Cruz-Guilloty F, Pipkin ME, Djuretic IM, Levanon D, Lotem J, Lichtenheld MG, Groner Y, Rao A. 
Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp 
Med. 2009 Jan 16;206(1):51-9. PubMed PMID: 19139168. PMCID: PMC2626671. 
23 
 
55. Milner JJ, Toma C, Yu B, Zhang K, Omilusik K, Phan AT, Wang D, Getzler AJ, Nguyen T, Crotty 
S, Wang W, Pipkin ME, Goldrath AW. Runx3 programs CD8(+) T cell residency in non-lymphoid tissues 
and tumours. Nature. 2017 Dec 14;552(7684):253-7. PubMed PMID: 29211713. 
56. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper 
T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J 
Immunol. 1986 Apr 01;136(7):2348-57. PubMed PMID: 2419430. 
57. Komine O, Hayashi K, Natsume W, Watanabe T, Seki Y, Seki N, Yagi R, Sukzuki W, Tamauchi H, 
Hozumi K, Habu S, Kubo M, Satake M. The Runx1 transcription factor inhibits the differentiation of 
naive CD4+ T cells into the Th2 lineage by repressing GATA3 expression. J Exp Med. 2003 Jul 
07;198(1):51-61. PubMed PMID: 12835475. PMCID: PMC2196077. 
58. Djuretic IM, Levanon D, Negreanu V, Groner Y, Rao A, Ansel KM. Transcription factors T-bet 
and Runx3 cooperate to activate Ifng and silence Il4 in T helper type 1 cells. Nat Immunol. 2007 
Feb;8(2):145-53. PubMed PMID: 17195845. 
59. Naoe Y, Setoguchi R, Akiyama K, Muroi S, Kuroda M, Hatam F, Littman DR, Taniuchi I. 
Repression of interleukin-4 in T helper type 1 cells by Runx/Cbf beta binding to the Il4 silencer. J Exp 
Med. 2007 Aug 06;204(8):1749-55. PubMed PMID: 17646405. PMCID: PMC2118685. 
60. Kohu K, Ohmori H, Wong WF, Onda D, Wakoh T, Kon S, Yamashita M, Nakayama T, Kubo M, 
Satake M. The Runx3 transcription factor augments Th1 and down-modulates Th2 phenotypes by 
interacting with and attenuating GATA3. J Immunol. 2009 Dec 15;183(12):7817-24. PubMed PMID: 
19933870. 
61. Yagi R, Junttila IS, Wei G, Urban JF, Jr., Zhao K, Paul WE, Zhu J. The transcription factor GATA3 
actively represses RUNX3 protein-regulated production of interferon-gamma. Immunity. 2010 Apr 
23;32(4):507-17. PubMed PMID: 20399120. PMCID: PMC2867662. 
62. Pham D, Vincentz JW, Firulli AB, Kaplan MH. Twist1 regulates Ifng expression in Th1 cells by 
interfering with Runx3 function. J Immunol. 2012 Jul 15;189(2):832-40. PubMed PMID: 22685315. 
PMCID: PMC3392532. 
63. Haagerup A, Bjerke T, Schiotz PO, Binderup HG, Dahl R, Kruse TA. Asthma and atopy - a total 
genome scan for susceptibility genes. Allergy. 2002 Aug;57(8):680-6. PubMed PMID: 12121185. 
64. Khader SA, Gaffen SL, Kolls JK. Th17 cells at the crossroads of innate and adaptive immunity 
against infectious diseases at the mucosa. Mucosal Immunol. 2009 Sep;2(5):403-11. PubMed PMID: 
19587639. PMCID: PMC2811522. 
65. Wang Y, Godec J, Ben-Aissa K, Cui K, Zhao K, Pucsek AB, Lee YK, Weaver CT, Yagi R, Lazarevic 
V. The transcription factors T-bet and Runx are required for the ontogeny of pathogenic interferon-
gamma-producing T helper 17 cells. Immunity. 2014 Mar 20;40(3):355-66. PubMed PMID: 24530058. 
PMCID: PMC3965587. 
66. Reis BS, Rogoz A, Costa-Pinto FA, Taniuchi I, Mucida D. Mutual expression of the transcription 
factors Runx3 and ThPOK regulates intestinal CD4(+) T cell immunity. Nat Immunol. 2013 
Mar;14(3):271-80. PubMed PMID: 23334789. PMCID: PMC3804366. 
67. Rudra D, Egawa T, Chong MM, Treuting P, Littman DR, Rudensky AY. Runx-CBFbeta 
complexes control expression of the transcription factor Foxp3 in regulatory T cells. Nat Immunol. 
2009 Nov;10(11):1170-7. PubMed PMID: 19767756. PMCID: PMC2764816. 
68. Kitoh A, Ono M, Naoe Y, Ohkura N, Yamaguchi T, Yaguchi H, Kitabayashi I, Tsukada T, Nomura 
T, Miyachi Y, Taniuchi I, Sakaguchi S. Indispensable role of the Runx1-Cbfbeta transcription complex 
for in vivo-suppressive function of FoxP3+ regulatory T cells. Immunity. 2009 Oct 16;31(4):609-20. 
PubMed PMID: 19800266. 
69. Bruno L, Mazzarella L, Hoogenkamp M, Hertweck A, Cobb BS, Sauer S, Hadjur S, Leleu M, 
Naoe Y, Telfer JC, Bonifer C, Taniuchi I, Fisher AG, Merkenschlager M. Runx proteins regulate Foxp3 
expression. J Exp Med. 2009 Oct 26;206(11):2329-37. PubMed PMID: 19841090. PMCID: 
PMC2768863. 
70. Klunker S, Chong MM, Mantel PY, Palomares O, Bassin C, Ziegler M, Ruckert B, Meiler F, Akdis 
M, Littman DR, Akdis CA. Transcription factors RUNX1 and RUNX3 in the induction and suppressive 
24 
 
function of Foxp3+ inducible regulatory T cells. J Exp Med. 2009 Nov 23;206(12):2701-15. PubMed 
PMID: 19917773. PMCID: PMC2806624. 
71. Nambu Y, Hayashi T, Jang KJ, Aoki K, Mano H, Nakano K, Osato M, Takahashi K, Itoh K, 
Teramukai S, Komori T, Fujita J, Ito Y, Shimizu A, Sugai M. In situ differentiation of CD8alphaalpha Tau 
cells from CD4 T cells in peripheral lymphoid tissues. Sci Rep. 2012;2:642. PubMed PMID: 22962636. 
PMCID: PMC3435563. 
72. Reis BS, Hoytema van Konijnenburg DP, Grivennikov SI, Mucida D. Transcription factor T-bet 
regulates intraepithelial lymphocyte functional maturation. Immunity. 2014 Aug 21;41(2):244-56. 
PubMed PMID: 25148025. PMCID: PMC4287410. 
73. Ohno S, Sato T, Kohu K, Takeda K, Okumura K, Satake M, Habu S. Runx proteins are involved 
in regulation of CD122, Ly49 family and IFN-gamma expression during NK cell differentiation. Int 
Immunol. 2008 Jan;20(1):71-9. PubMed PMID: 18003603. 
74. Guo Y, Maillard I, Chakraborti S, Rothenberg EV, Speck NA. Core binding factors are necessary 
for natural killer cell development and cooperate with Notch signaling during T-cell specification. 
Blood. 2008 Aug 01;112(3):480-92. PubMed PMID: 18390836. PMCID: PMC2481540. 
75. Levanon D, Negreanu V, Lotem J, Bone KR, Brenner O, Leshkowitz D, Groner Y. Transcription 
factor Runx3 regulates interleukin-15-dependent natural killer cell activation. Mol Cell Biol. 2014 
Mar;34(6):1158-69. PubMed PMID: 24421391. PMCID: PMC3958033. 
76. Liu Q, Jin WN, Liu Y, Shi K, Sun H, Zhang F, Zhang C, Gonzales RJ, Sheth KN, La Cava A, Shi FD. 
Brain Ischemia Suppresses Immunity in the Periphery and Brain via Different Neurogenic 
Innervations. Immunity. 2017 Mar 21;46(3):474-87. PubMed PMID: 28314594. 
77. Lai CB, Mager DL. Role of runt-related transcription factor 3 (RUNX3) in transcription 
regulation of natural cytotoxicity receptor 1 (NCR1/NKp46), an activating natural killer (NK) cell 
receptor. J Biol Chem. 2012 Mar 02;287(10):7324-34. PubMed PMID: 22253448. PMCID: 
PMC3293567. 
78. Ebihara T, Song C, Ryu SH, Plougastel-Douglas B, Yang L, Levanon D, Groner Y, Bern MD, 
Stappenbeck TS, Colonna M, Egawa T, Yokoyama WM. Runx3 specifies lineage commitment of innate 
lymphoid cells. Nat Immunol. 2015 Nov;16(11):1124-33. PubMed PMID: 26414766. PMCID: 
PMC4618046. 
79. Gunnell A, Webb HM, Wood CD, McClellan MJ, Wichaidit B, Kempkes B, Jenner RG, Osborne 
C, Farrell PJ, West MJ. RUNX super-enhancer control through the Notch pathway by Epstein-Barr 
virus transcription factors regulates B cell growth. Nucleic Acids Res. 2016 Jun 02;44(10):4636-50. 
PubMed PMID: 26883634. PMCID: PMC4889917. 
80. Spender LC, Cornish GH, Sullivan A, Farrell PJ. Expression of transcription factor AML-2 
(RUNX3, CBF(alpha)-3) is induced by Epstein-Barr virus EBNA-2 and correlates with the B-cell 
activation phenotype. J Virol. 2002 May;76(10):4919-27. PubMed PMID: 11967309. PMCID: 
PMC136164. 
81. Spender LC, Whiteman HJ, Karstegl CE, Farrell PJ. Transcriptional cross-regulation of RUNX1 
by RUNX3 in human B cells. Oncogene. 2005 Mar 10;24(11):1873-81. PubMed PMID: 15688019. 
82. Boyaka PN. Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems. J 
Immunol. 2017 Jul 01;199(1):9-16. PubMed PMID: 28630108. 
83. Shi MJ, Stavnezer J. CBF alpha3 (AML2) is induced by TGF-beta1 to bind and activate the 
mouse germline Ig alpha promoter. J Immunol. 1998 Dec 15;161(12):6751-60. PubMed PMID: 
9862705. 
84. Manis JP, Tian M, Alt FW. Mechanism and control of class-switch recombination. Trends 
Immunol. 2002 Jan;23(1):31-9. PubMed PMID: 11801452. 
85. Zhang Y, Derynck R. Transcriptional regulation of the transforming growth factor-beta -
inducible mouse germ line Ig alpha constant region gene by functional cooperation of Smad, CREB, 
and AML family members. J Biol Chem. 2000 Jun 02;275(22):16979-85. PubMed PMID: 10748032. 
86. Pardali E, Xie XQ, Tsapogas P, Itoh S, Arvanitidis K, Heldin CH, ten Dijke P, Grundstrom T, 
Sideras P. Smad and AML proteins synergistically confer transforming growth factor beta1 
25 
 
responsiveness to human germ-line IgA genes. J Biol Chem. 2000 Feb 04;275(5):3552-60. PubMed 
PMID: 10652350. 
87. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, Imamura T, Ishidou Y, Fukuchi 
M, Shi MJ, Stavnezer J, Kawabata M, Miyazono K, Ito Y. Interaction and functional cooperation of 
PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. J 
Biol Chem. 1999 Oct 29;274(44):31577-82. PubMed PMID: 10531362. 
88. Watanabe K, Sugai M, Nambu Y, Osato M, Hayashi T, Kawaguchi M, Komori T, Ito Y, Shimizu 
A. Requirement for Runx proteins in IgA class switching acting downstream of TGF-beta 1 and 
retinoic acid signaling. J Immunol. 2010 Mar 15;184(6):2785-92. PubMed PMID: 20142360. 
89. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and 
adult fibroblast cultures by defined factors. Cell. 2006 Aug 25;126(4):663-76. PubMed PMID: 
16904174. Epub 2006/08/15. eng. 
90. Xu J, Du Y, Deng H. Direct lineage reprogramming: strategies, mechanisms, and applications. 
Cell Stem Cell. 2015 Feb 5;16(2):119-34. PubMed PMID: 25658369. 
91. Chambers SM, Studer L. Cell fate plug and play: direct reprogramming and induced 
pluripotency. Cell. 2011 Jun 10;145(6):827-30. PubMed PMID: 21663788. 
92. Srivastava D, DeWitt N. In Vivo Cellular Reprogramming: The Next Generation. Cell. 2016 Sep 
8;166(6):1386-96. PubMed PMID: 27610565. 
93. Ang CE, Wernig M. Induced neuronal reprogramming. J Comp Neurol. 2014 Aug 
15;522(12):2877-86. PubMed PMID: 24771471. PMCID: PMC4099045. 
94. Batta K, Florkowska M, Kouskoff V, Lacaud G. Direct reprogramming of murine fibroblasts to 
hematopoietic progenitor cells. Cell Rep. 2014 Dec 11;9(5):1871-84. PubMed PMID: 25466247. 
PMCID: PMC4542300. 
95. Pereira CF, Chang B, Qiu J, Niu X, Papatsenko D, Hendry CE, Clark NR, Nomura-Kitabayashi A, 
Kovacic JC, Ma'ayan A, Schaniel C, Lemischka IR, Moore K. Induction of a hemogenic program in 
mouse fibroblasts. Cell Stem Cell. 2013 Aug 1;13(2):205-18. PubMed PMID: 23770078. PMCID: 
PMC3735774. 
96. Feng R, Desbordes SC, Xie H, Tillo ES, Pixley F, Stanley ER, Graf T. PU.1 and C/EBPalpha/beta 
convert fibroblasts into macrophage-like cells. Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6057-
62. PubMed PMID: 18424555. PMCID: PMC2327209. 
97. Szabo E, Rampalli S, Risueno RM, Schnerch A, Mitchell R, Fiebig-Comyn A, Levadoux-Martin 
M, Bhatia M. Direct conversion of human fibroblasts to multilineage blood progenitors. Nature. 2010 
Nov 25;468(7323):521-6. PubMed PMID: 21057492. 
98. Elcheva I, Brok-Volchanskaya V, Kumar A, Liu P, Lee JH, Tong L, Vodyanik M, Swanson S, 
Stewart R, Kyba M, Yakubov E, Cooke J, Thomson JA, Slukvin I. Direct induction of 
haematoendothelial programs in human pluripotent stem cells by transcriptional regulators. Nat 
Commun. 2014 Jul 14;5:4372. PubMed PMID: 25019369. PMCID: PMC4107340. 
99. Doulatov S, Vo LT, Chou SS, Kim PG, Arora N, Li H, Hadland BK, Bernstein ID, Collins JJ, Zon LI, 
Daley GQ. Induction of multipotential hematopoietic progenitors from human pluripotent stem cells 
via respecification of lineage-restricted precursors. Cell Stem Cell. 2013 Oct 3;13(4):459-70. PubMed 
PMID: 24094326. PMCID: PMC3888026. 
100. Kyba M, Perlingeiro RC, Daley GQ. HoxB4 confers definitive lymphoid-myeloid engraftment 
potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell. 2002 Apr 5;109(1):29-
37. PubMed PMID: 11955444. 
101. Sugimura R, Jha DK, Han A, Soria-Valles C, da Rocha EL, Lu YF, Goettel JA, Serrao E, Rowe RG, 
Malleshaiah M, Wong I, Sousa P, Zhu TN, Ditadi A, Keller G, Engelman AN, Snapper SB, Doulatov S, 
Daley GQ. Haematopoietic stem and progenitor cells from human pluripotent stem cells. Nature. 
2017 May 25;545(7655):432-8. PubMed PMID: 28514439. 
102. Wang Y, Yates F, Naveiras O, Ernst P, Daley GQ. Embryonic stem cell-derived hematopoietic 
stem cells. Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19081-6. PubMed PMID: 16357205. PMCID: 
PMC1323159. 
26 
 
103. Yamamizu K, Piao Y, Sharov AA, Zsiros V, Yu H, Nakazawa K, Schlessinger D, Ko MS. 
Identification of transcription factors for lineage-specific ESC differentiation. Stem Cell Reports. 
2013;1(6):545-59. PubMed PMID: 24371809. PMCID: PMC3871400. 
104. Zaret KS, Carroll JS. Pioneer transcription factors: establishing competence for gene 
expression. Genes Dev. 2011 Nov 1;25(21):2227-41. PubMed PMID: 22056668. PMCID: PMC3219227. 
105. Wapinski OL, Vierbuchen T, Qu K, Lee QY, Chanda S, Fuentes DR, Giresi PG, Ng YH, Marro S, 
Neff NF, Drechsel D, Martynoga B, Castro DS, Webb AE, Sudhof TC, Brunet A, Guillemot F, Chang HY, 
Wernig M. Hierarchical mechanisms for direct reprogramming of fibroblasts to neurons. Cell. 2013 
Oct 24;155(3):621-35. PubMed PMID: 24243019. PMCID: PMC3871197. 
106. Sekiya S, Suzuki A. Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined 
factors. Nature. 2011 Jun 29;475(7356):390-3. PubMed PMID: 21716291. 
107. Lis R, Karrasch CC, Poulos MG, Kunar B, Redmond D, Duran JGB, Badwe CR, Schachterle W, 
Ginsberg M, Xiang J, Tabrizi AR, Shido K, Rosenwaks Z, Elemento O, Speck NA, Butler JM, Scandura 
JM, Rafii S. Conversion of adult endothelium to immunocompetent haematopoietic stem cells. 
Nature. 2017 May 25;545(7655):439-45. PubMed PMID: 28514438. 
108. Sandler VM, Lis R, Liu Y, Kedem A, James D, Elemento O, Butler JM, Scandura JM, Rafii S. 
Reprogramming human endothelial cells to haematopoietic cells requires vascular induction. Nature. 
2014 Jul 17;511(7509):312-8. PubMed PMID: 25030167. PMCID: PMC4159670. 
109. Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fucikova J, Cremer I, Galon J, Tartour E, 
Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based interventions for cancer therapy. 
Oncoimmunology. 2013 Oct 1;2(10):e25771. PubMed PMID: 24286020. PMCID: PMC3841205. 
110. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: 
Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016 Mar 2;8(328):328rv4. 
PubMed PMID: 26936508. PMCID: PMC4859220. 
111. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, 
Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Jr., Gascon P, Lotem M, 
Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus 
dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-
26. PubMed PMID: 21639810. 
112. Chodon T, Koya RC, Odunsi K. Active Immunotherapy of Cancer. Immunol Invest. 
2015;44(8):817-36. PubMed PMID: 26575466. 
113. Lim WA, June CH. The Principles of Engineering Immune Cells to Treat Cancer. Cell. 2017 Feb 
9;168(4):724-40. PubMed PMID: 28187291. PMCID: PMC5553442. 
114. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to 
Cancer Immunotherapy. Cell. 2017 Feb 9;168(4):707-23. PubMed PMID: 28187290. PMCID: 
PMC5391692. 
 
FIGURE LEGEND 
FIGURE 1. The major effects of RUNX3 on the phenotype of various dendritic cell (DC) 
subsets. The impacts of RUNX3 in TGF-β activated monocyte-derived DCs, in CD4+ splenic 
DCs and in embryonic stem cell derived dendritic cells (ES-DCs). 
FIGURE 2. RUNX3 stimulated CD8+ T cell development. Here, we summarize the effects of 
RUNX3 on cytotoxic T cells. 
27 
 
FIGURE 3. RUNX3 instructed Th1 polarization. Here, we summarize the effects of RUNX3 
upon the development of Th1/Th2 cells. 
FIGURE 4. The major effects of RUNX3 on the phenotype of B and NK cells. 
 
28 
 
 
 
29 
 
 
